8/19/25: Long COVID clinical trials addressing viral persistence, immune dysfunction

In this episode of Still Here: A two-way between Miles Griffis and Betsy Ladyzhets comparing and contrasting Long COVID and ME clinical trial designs for drugs targeting immune dysregulation and viral persistence.The transcript for this episode can be ⁠⁠⁠found on our website⁠⁠⁠, or jump to a specific part of the podcast below: (00:00:00) Intro(00:01:05) 2-way: Long COVID clinical trial design for JAK inhibitors, drugs targeting viral persistence(00:28:37) Outro-Mentioned in this episode (in order of appearance):The Sick Times: Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulationThe Sick Times: No “easy home runs”: Early Long COVID trials of Paxlovid and monoclonal antibodies failed, but the treatments still have potentialThe Sick Times: Research updates, July 8The Sick Times: Invivyd Chairman Marc Elia: The bureaucracy is killing people with Long COVIDStill Here: February 25: Links and transcriptAdditional audio in this episode: Rude Mechanical Orchestra: Which Side Are You On? (orig. Florence Reece)